Yuliang Wu

1239 Siping Road
Shanghai, 200092, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

PiggyBac-engineered membrane-bound IL-7 TILs combined with anti-PD-1 antibody demonstrates efficacy in recurrent ovarian cancer: a first-in-human phase 1 trial.

PiggyBac-engineered membrane-bound IL-7 TILs combined with anti-PD-1 antibody demonstrates efficacy in recurrent ovarian cancer: a first-in-human phase 1 trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 29, 2025

PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.

PiggyBac-Engineered Membrane-Bound IL7 TILs Combined with Anti-PD-1 Antibody Demonstrates Efficacy in Recurrent Ovarian Cancer: A First-in-Human Phase I Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 29, 2025

Single-cell RNA sequencing reveals tumor microenvironment characteristics in ovarian malignant Brenner tumor.

Single-cell RNA sequencing reveals tumor microenvironment characteristics in ovarian malignant Brenner tumor.

Journal: Genes & diseases

Published: December 09, 2024

Exploring the Potential Value of Modulation of Cell Death in Immunotherapy of Gynecological Tumors.

Exploring the Potential Value of Modulation of Cell Death in Immunotherapy of Gynecological Tumors.

Journal: Gynecology and minimally invasive therapy

Published: August 01, 2024

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.

IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer.

Journal: BMC medicine

Published: October 03, 2023

Umbilical cord blood-derived neutrophils possess higher viability than peripheral blood derived neutrophils.

Umbilical cord blood-derived neutrophils possess higher viability than peripheral blood derived neutrophils.

Journal: American journal of cancer research

Published: September 15, 2023

MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.

MUC16 stimulates neutrophils to an inflammatory and immunosuppressive phenotype in ovarian cancer.

Journal: Journal of ovarian research

Published: November 06, 2022

Identification of TRPM2 as a prognostic factor correlated with immune infiltration in ovarian cancer.

Identification of TRPM2 as a prognostic factor correlated with immune infiltration in ovarian cancer.

Journal: Journal of ovarian research

Published: October 17, 2022

Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.

Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.

Journal: Frontiers in molecular biosciences

Published: June 07, 2022

Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.

Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.

Journal: Frontiers in molecular biosciences

Published: July 18, 2021

LPS and IL-8 activated umbilical cord blood-derived neutrophils inhibit the progression of ovarian cancer.

LPS and IL-8 activated umbilical cord blood-derived neutrophils inhibit the progression of ovarian cancer.

Journal: Journal of Cancer

Published: October 09, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026